


VICTORIA

#ACC20/#WCCardio



AMERICAN
COLLEGE of
CARDIOLOGY

Trial Description: Patients with chronic heart failure were randomized to vericiguat 10 mg daily versus placebo.



RESULTS

- Primary outcome, cardiovascular death or hospitalization for heart failure: 35.5% of the vericiguat group vs. 38.5% of the placebo group (p = 0.019)
- All-cause death: 20.3% with vericiguat vs. 21.2% with placebo (p = 0.38)
- Heart failure hospitalization: 27.4% with vericiguat vs. 29.6% with placebo (p = 0.048)

CONCLUSIONS

- Among patients with chronic heart failure with recent decompensation, a novel strategy of increasing soluble guanylate cyclase activity with vericiguat was effective
- Vericiguat vs. placebo was effective at reducing cardiovascular death or hospitalization for heart failure

Armstrong PW, et al. N Engl J Med 2020;Mar 28:[Epub]